Roche Holdings AG Basel (OTCMKTS:RHHBY) and Capgemini (OTCMKTS:CGEMY) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.
This table compares Roche Holdings AG Basel and Capgemini’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Roche Holdings AG Basel||N/A||N/A||N/A|
Institutional & Insider Ownership
0.3% of Roche Holdings AG Basel shares are held by institutional investors. Comparatively, 0.2% of Capgemini shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This is a breakdown of current ratings and recommmendations for Roche Holdings AG Basel and Capgemini, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Roche Holdings AG Basel||3||3||3||0||2.00|
Roche Holdings AG Basel presently has a consensus target price of $34.00, indicating a potential upside of 8.64%. Given Roche Holdings AG Basel’s higher probable upside, equities research analysts clearly believe Roche Holdings AG Basel is more favorable than Capgemini.
Valuation and Earnings
This table compares Roche Holdings AG Basel and Capgemini’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Roche Holdings AG Basel||$54.15 billion||3.94||$8.77 billion||$1.95||16.05|
|Capgemini||$14.45 billion||1.46||$926.84 million||N/A||N/A|
Roche Holdings AG Basel has higher revenue and earnings than Capgemini.
Volatility and Risk
Roche Holdings AG Basel has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Capgemini has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500.
Roche Holdings AG Basel pays an annual dividend of $0.89 per share and has a dividend yield of 2.8%. Capgemini pays an annual dividend of $0.28 per share and has a dividend yield of 1.1%. Roche Holdings AG Basel pays out 45.6% of its earnings in the form of a dividend.
Roche Holdings AG Basel beats Capgemini on 7 of the 9 factors compared between the two stocks.
Roche Holdings AG Basel Company Profile
Roche Holding AG engages in the diagnostics and pharmaceuticals businesses in Switzerland, Germany, and rest of Europe. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, liver, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus diseases. The company provides diagnostic solutions, such as blood gas analysis; blood screening; cancer screening/monitoring; cardiac markers; cardiovascular testing; cholesterol monitoring; coagulation monitoring; coagulation routine and specialty testing; data management; diabetes monitoring; diabetes therapy; electrolytes analysis; emergency medicine; hemostasis; heterogeneous immunochemistry; homogeneous immuno assays; immunology; infectious diseases; intensive care testing; monitoring anti platelet therapy; neonatal intensive care units; nucleic acid purification; PCR clinical diagnostics; physical fitness testing; platelet function testing; quality control service; real-time PCR diagnostic systems; serum work area; urinalysis; and workflow solutions. Roche Holding AG has a strategic alliance with Wisconsin Diagnostic Laboratories; and collaboration agreements with Five Prime Therapeutics, Inc., Ionis Pharmaceuticals, Inc., and SQZ Biotechnologies Company. The company was founded in 1896 and is headquartered in Basel, Switzerland.
Capgemini Company Profile
Capgemini SE provides consulting, technology, and digital transformation services. It addresses clients' opportunities in the world of cloud, digital, and platforms, as well as enables organizations to realize business ambitions through an array of services from strategy to operations. The company's Consulting Services segment offers strategy and transformation consulting services primarily in digital transformation that enhance the performance of organizations based on intimate client relationships, and the knowledge of client industries and processes. Its Technology & Engineering Services segment provides assistance and support to internal IT teams of client companies. The company's Application Services segment designs, develops, implements, and maintains IT applications, including system integration and application maintenance services. Its Other Managed Services segment integrates, manages, and/or develops client's IT infrastructure systems, as well as provides transaction, on-demand, and/or business process outsourcing services. The company also provides financial services, as well as manages the business activities of clients in financial sector. Capgemini SE serves various industries, including aerospace and defense, automotive, consumer products and retail, electronics and high tech, government and public sector, healthcare and life sciences, insurance, media and entertainment, natural resources, telecom, transportation and distribution, and utilities. The company has operations in North America, France, the United Kingdom, Ireland, rest of Europe, Asia-Pacific, and Latin America. Capgemini SE was founded in 1967 and is based in Paris, France.
Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.